Asset Details
Do you wish to reserve the book?
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Do you wish to request the book?
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012
Overview
In a study involving nearly 1200 men with metastatic prostate cancer who had progressive disease after chemotherapy, enzalutamide, a novel androgen-receptor blocker, extended the median survival by nearly 5 months, as compared with placebo (18 months vs. 13 months).
Prostate cancer is an androgen-dependent disease that initially responds but later becomes resistant to established therapies that reduce circulating testosterone levels or inhibit androgen binding to the androgen receptor.
1
–
4
Reactivation of the disease despite castrate levels of testosterone represents a transition to the lethal phenotype of castration-resistant prostate cancer.
5
,
6
This state was previously called androgen-independent or hormone-refractory prostate cancer but is now recognized to be driven by androgen-receptor signaling, in part due to overexpression of the androgen receptor itself.
7
,
8
In preclinical models of prostate cancer, androgen-receptor overexpression shortens the period of tumor latency and confers resistance to . . .
Publisher
Massachusetts Medical Society
Subject
/ Androgen Receptor Antagonists - adverse effects
/ Androgen Receptor Antagonists - therapeutic use
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Diarrhea
/ Fatigue
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Male
/ Men
/ Neoplasm Metastasis - drug therapy
/ Nephrology. Urinary tract diseases
/ Pain
/ Phenylthiohydantoin - adverse effects
/ Phenylthiohydantoin - analogs & derivatives
/ Phenylthiohydantoin - therapeutic use
/ Prostatic Neoplasms - drug therapy
/ Prostatic Neoplasms - mortality
/ Prostatic Neoplasms - surgery
/ Seizures
/ Seizures - chemically induced
/ Signal Transduction - drug effects
/ Survival
/ Tumors
